UDP glucuronosyltransferase family 2 member B17Genealiases: BMND12 · UDPGT2B17
Q-omics provides the consensus-scored UGT2B17 profile across patient tissues and cancer cell-line models. UGT2B17 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, UGT2B17 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, UGT2B17 RNA expression shows 7,623 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where UGT2B17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT2B17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT2B17 survival associations across molecular data types. UGT2B17 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT2B17 RNA expression–survival associations across cancer types. High UGT2B17 expression shows unfavorable associations in LGG, but favorable associations in MESO, PAAD, KIRC, LUAD and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for UGT2B17 RNA expression.
This table summarizes UGT2B17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UGT2B17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT2B17 shows lower tumor expression in COAD, KICH, READ and CHOL and higher tumor expression in KIRC and BLCA. The KIRC box plot shows higher UGT2B17 RNA expression in tumor versus normal tissue (log2 FC = +0.617, t-test p < 0.001).
This table shows molecular features associated with UGT2B17 in patient tissues and cancer cell lines. In patient samples, UGT2B17 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UGT2B17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_NSCLC_LUAD.
